Yes, methimazole should be resumed immediately at 22 weeks gestation with suppressed TSH and elevated free T4.
This patient has active, inadequately controlled hyperthyroidism in the second trimester that requires urgent treatment to prevent serious maternal and fetal complications including preeclampsia, intrauterine growth restriction, preterm delivery, and fetal death 1.
Critical Clinical Context
Your patient's labs demonstrate:
- Suppressed TSH (<0.02 → 0.011 µIU/mL): Indicates active hyperthyroidism
- Elevated free T4 (26.7 pmol/L → 1.53 ng/dL): The first value is markedly elevated; the second (1.53 ng/dL) appears to still be above normal pregnancy ranges
- Two-month gap without treatment: This is dangerously long for uncontrolled maternal hyperthyroidism
Why Treatment Must Be Resumed
Inadequately treated maternal thyrotoxicosis carries severe risks 1:
- Medically indicated preterm delivery
- Intrauterine growth restriction and low birth weight
- Pre-eclampsia
- Congestive heart failure
- Fetal death
The evidence is unequivocal: undertreatment of maternal hyperthyroidism can lead to central congenital hypothyroidism and fetal complications 1. Conversely, while overtreatment with thioamides can cause iatrogenic fetal hypothyroidism, this is manageable with dose adjustment 1.
Methimazole is the Correct Choice at 22 Weeks
At 22 weeks gestation (second trimester), methimazole is the preferred antithyroid drug 2, 3, 4:
- First trimester concern resolved: The teratogenic risk of methimazole (aplasia cutis, choanal atresia, esophageal atresia) is confined to first-trimester organogenesis 3
- PTU hepatotoxicity risk: Propylthiouracil carries risk of severe hepatotoxicity, particularly problematic beyond the first trimester 1, 2
- Guideline recommendation: Switch from PTU to methimazole after the first trimester, or continue methimazole if already past organogenesis 2, 4
Dosing and Monitoring Strategy
Start with adapted-dose strategy 2:
- Resume methimazole at 5-10 mg daily initially (lower than her previous 20 mg given the 2-month gap)
- Goal: Maintain maternal free T4 in the upper third of the trimester-specific reference range 2, 5
- TSH may remain suppressed throughout pregnancy and cannot guide therapy alone 2
Monitoring schedule 2:
- Check thyroid function every 2 weeks initially, then every 2-4 weeks once stable
- Adjust dose based primarily on free T4 levels
- Consider checking TRAb (thyroid receptor antibodies) if not already done, especially given history of Graves' disease 1
Critical Pitfalls to Avoid
Do not delay treatment: Every week of uncontrolled hyperthyroidism increases maternal-fetal risk 1
Do not aim for "normal" TSH: TSH suppression is expected in treated Graves' disease during pregnancy; free T4 is your primary guide 2
Monitor for fetal thyroid dysfunction: At 22 weeks, fetal ultrasound should assess for goiter, growth restriction, tachycardia (>160 bpm), or hydrops 1. If TRAb levels are >3× upper normal limit, fetal hyperthyroidism risk increases 1
Use lowest effective dose: The goal is maternal euthyroidism without fetal hypothyroidism 1, 3
Additional Considerations
- Determine etiology: Confirm this is Graves' disease (not gestational transient thyrotoxicosis) by checking TRAb if not previously documented 1
- Liver function: Baseline liver enzymes given methimazole's (rare) hepatotoxicity risk 3
- Patient counseling: Explain the critical importance of adherence and the risks of untreated hyperthyroidism 3
- Postpartum planning: Graves' disease commonly relapses postpartum; plan for close monitoring 2
The evidence strongly supports immediate resumption of methimazole with close monitoring to optimize both maternal and fetal outcomes.